Skip to content

Study · Randomized controlled trial · 2017

4 results

Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.

Wysham C, Bonadonna RC, Aroda VR, Puig Domingo M, Kapitza C, Stager W, Yu C, Niemoeller E, Souhami E, Bergenstal RM

Diabetes, obesity & metabolism8 Jun 2017Cited by 26 (Europe PMC)

PMID28386990 (opens in a new tab)PMCIDPMC5638095 (opens in a new tab)DOI10.1111/dom.12961 (opens in a new tab)PepBankPUB-28386990
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, iGlarLixi reduced HbA1c more than insulin glargine across baseline subgroups (P < .0001).

    In plain wordsIn patients with diabetes, iGlarLixi reduced HbA1c more than insulin glargine across baseline subgroups.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c reduction
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Measurements

    P value
    < 0.0001
    iGlarLixi vs iGlar, all subpopulations

    Source sentences

    Summary
    Compared with the iGlar treatment group, patients treated with iGlarLixi showed consistently greater reductions in HbA1c during the treatment period, with higher percentages of patients achieving the HbA1c target level of <7% (<53 mmol/mol) in all of the subpopulations tested (P < .0001 for all),
    1 context sentence
    Summary · context
    a randomized open-label trial designed to evaluate the efficacy and safety of iGlarLixi, a novel fixed-ratio combination of insulin glargine 100 U (iGlar) plus lixisenatide, in comparison with iGlar over 30 weeks
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, more iGlarLixi patients achieved HbA1c <7% than insulin glargine patients across baseline subgroups.

    In plain wordsIn patients with diabetes, more iGlarLixi patients achieved the HbA1c target than insulin glargine patients across baseline subgroups.

    Peptide
    Lixisenatide
    Outcome
    IncreaseHbA1c target below 7%
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Measurements

    P value
    < 0.0001
    iGlarLixi vs iGlar, all subpopulations

    Source sentences

    Summary
    Compared with the iGlar treatment group, patients treated with iGlarLixi showed consistently greater reductions in HbA1c during the treatment period, with higher percentages of patients achieving the HbA1c target level of <7% (<53 mmol/mol) in all of the subpopulations tested (P < .0001 for all),
    1 context sentence
    Summary · context
    a randomized open-label trial designed to evaluate the efficacy and safety of iGlarLixi, a novel fixed-ratio combination of insulin glargine 100 U (iGlar) plus lixisenatide, in comparison with iGlar over 30 weeks
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, iGlarLixi mitigated weight gain compared with insulin glargine across baseline subgroups.

    In plain wordsIn patients with diabetes, iGlarLixi limited weight gain compared with insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    DecreaseBody weight gain
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    having consistent mitigation of body weight gain and with no major differences in the incidence of hypoglycaemia.
    1 context sentence
    Summary · context
    a randomized open-label trial designed to evaluate the efficacy and safety of iGlarLixi, a novel fixed-ratio combination of insulin glargine 100 U (iGlar) plus lixisenatide, in comparison with iGlar over 30 weeks
  4. 04HumanRandomized controlled trialSafety outcome

    In patients with type 2 diabetes, hypoglycaemia incidence showed no major differences between iGlarLixi and insulin glargine.

    In plain wordsIn patients with diabetes, hypoglycaemia incidence showed no major differences between iGlarLixi and insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedHypoglycaemia incidence
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    having consistent mitigation of body weight gain and with no major differences in the incidence of hypoglycaemia.
    1 context sentence
    Summary · context
    a randomized open-label trial designed to evaluate the efficacy and safety of iGlarLixi, a novel fixed-ratio combination of insulin glargine 100 U (iGlar) plus lixisenatide, in comparison with iGlar over 30 weeks

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02058160

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

Sanofin = 736Jan 2014 to Jul 2015

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 9 May 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.